95 results on '"Forconi, Francesco"'
Search Results
2. The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
3. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
4. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
5. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
6. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
7. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
8. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
9. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
10. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
11. IL-4 enhances expression and function of surface IgM in CLL cells
12. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation
13. Perturbation of the normal immune system in patients with CLL
14. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
15. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
16. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
17. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
18. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
19. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
20. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
21. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
22. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
23. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
24. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
25. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
26. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
27. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
28. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
29. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
30. The normal IGHV1-69–derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL
31. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
32. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
33. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
34. EMT-like Activation in CLL Provides Novel Therapeutic Target
35. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch
36. Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance
37. Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia
38. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
39. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
40. Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology
41. Lymphoma-Specific Subversion of B-Cell Receptor Signaling By Macrophage Lectins
42. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
43. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM)
44. The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells
45. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation
46. Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia
47. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
48. BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia
49. Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL
50. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.